Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Cash (2023 - 2025)

Historic Change in Cash for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $138.9 million.

  • Monte Rosa Therapeutics' Change in Cash rose 72834.82% to $138.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 2377.07%. This contributed to the annual value of $96.4 million for FY2024, which is 3303.17% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Change in Cash stood at $138.9 million, which was up 72834.82% from -$9.0 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Change in Cash high stood at $138.9 million for Q3 2025, and its period low was -$145.7 million during Q1 2025.
  • Its 3-year average for Change in Cash is $13.9 million, with a median of $9.1 million in 2024.
  • In the last 5 years, Monte Rosa Therapeutics' Change in Cash tumbled by 81659.05% in 2024 and then soared by 72834.82% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Change in Cash (Quarter) stood at $69.1 million in 2023, then surged by 42.73% to $98.6 million in 2024, then surged by 40.84% to $138.9 million in 2025.
  • Its last three reported values are $138.9 million in Q3 2025, -$9.0 million for Q2 2025, and -$145.7 million during Q1 2025.